stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs BioNTech SE Sponsored ADR (BNTX)
- Alnylam Pharmaceuticals, Inc. ALNY 157.11 +0.29%
- BioNTech SE Sponsored ADR BNTX 87.18 +1.54%
Alnylam Pharmaceuticals, Inc. and BioNTech SE Sponsored ADR are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. and BioNTech SE Sponsored ADR are of similar size ($21.6B and $21.0B). BioNTech SE Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Alnylam Pharmaceuticals, Inc. trades at 7.9×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against −22.7%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs −63.8%) and the higher return on invested capital (59.4% vs −34.3%). Across the 18 metrics below, Alnylam Pharmaceuticals, Inc. leads on 14 and BioNTech SE Sponsored ADR on 4.
Valuation
Profitability
| Metric | ALNY | BNTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 74.59% | 65.16% |
| Operating margin | 19.50% | (78.99%) | 0.00% |
| Net margin | 52.85% | (63.77%) | 0.00% |
| Free cash flow margin | 16.08% | (19.21%) | 0.00% |
| Return on equity | 138.07% | (8.29%) | (50.12%) |
| Return on assets | 41.25% | (7.22%) | (45.60%) |
| Return on invested capital | 59.37% | (34.28%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack